Search form

 

Press Releases


Axcan Pharma to Present at UBS Global Specialty Pharmaceuticals Conference in New York City


May 18, 2005 - 11:59 ET

MONT SAINT-HILAIRE, Quebec, May 18 - Axcan Pharma Inc.
("Axcan" or the "Company") today announced that on Monday, May 23, 2005, its
Executive Vice-President and Chief Operating Officer, David W. Mims, will
present an overview of the Company at the UBS Global Pharmaceuticals
Conference held in New York City. This presentation will take place at
11:00 A.M. ET.

Interested parties can access the audio webcast of the presentation on
the Company's website at www.axcan.com .


Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology. The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and
Europe. Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

"Safe Harbor" statement under the Private Securities Litigation Reform
Act of 1995.

This release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. To the extent any
statements made in this release contain information that is not historical,
these statements are essentially forward looking and are often identified by
words such as "anticipate," "expect," "estimate," "intend," "project," "plan"
and "believe." Forward-looking statements are subject to risks and
uncertainties, including the difficulty of predicting FDA and other regulatory
approvals, acceptance and demand for new pharmaceutical products, the impact
of competitive products and pricing, new product development and launch,
reliance on key strategic alliances, availability of raw materials, the
regulatory environment, fluctuations in operating results , the protection of
our intellectual property and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission and the Canadian
securities regulatory authorities.



For further information: Julie M. Thibodeau, Manager, Investor
Relations, Axcan Pharma Inc., (450) 467-5138 ext. 2062, www.axcan.com;
Source: AXCAN PHARMA INC.